

COMPLEX REGIONAL PAIN SYNDROME

MICHAEL VELTMAN
MBBS FANZCA FASE FFPMANZCA



OUTLINE

Definition

Diagnosis

Pathophysiology

Management

WHAT IS CRPS

Lots of confusion about what this condition is:

“Reflex Sympathetic Dystrophy”

Multiple diagnostic criteria historically

IASP Budapest Criteria (1998) have the best acceptance.

Type I - With no nerve injury

Type II - With nerve injury

CRPS is a condition that should primarily be managed by pain specialists

EPIDEMIOLOGY

26.2 per 100 000 life years

c.f. RA 30/100 000, MS 4/100 000

Females 3.5:1

Upper limbs 60%

Type I most common

Increases with age - peak at 55 - 70 years

ECONOMIC COSTS

Major costs to the community of CRPS

High levels of morbidity.

More pain and dysfunction than either rheumatoid arthritis or fibromyalgia.

Average health care costs were 5700 euros in 1998 - much higher now.

INCITING EVENTS

Peripheral musculoskeletal

Fractures 45%

Sprains 18%

Elective surgery 12%

Nerve injury - Peripheral & Central

Other - CNS, Visceral

Idiopathic - 10%

OTHER ASSOCIATED FACTORS

Caucasian race

Higher median income

Depression

Drug abuse

Pre-existing pain conditions:

Fibromyalgia

Headache

PROTECTIVE FACTORS

Associations with lower rates of CRPS

Obesity

Diabetes

Hypothyroidism

Anaemia



PainScience

DIAGNOSIS

BUDAPEST CRITERIA

Consensus meeting in 2003

Improvement on previous IASP criteria

- ◆ Sensitivity 85%
- ◆ Specificity: 69%
- ◆ 3 Symptoms
- ◆ 2 Signs

IASP Clinical Budapest Criteria in diagnosing CRPS

- 1. Continuing pain that is disproportionate to any inciting event**
- 2. At least one symptom reported in at least three of the following categories:**

Sensory	Hyperesthesia or allodynia
Vasomotor	Temperature asymmetry, skin color changes, skin color asymmetry
Sudomotor	Edema, sweating changes, sweating asymmetry
Motor/trophic	Decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin)
- 3. At least one sign at time of evaluation in at least two of the following categories:**

Sensory	Evidence of hyperalgesia (to pinprick), allodynia (to light touch, temperature sensation, deep somatic pressure or joint movement)
Vasomotor	Evidence of temperature asymmetry (>1 C°), skin color changes or asymmetry
Sudomotor	Evidence of edema, sweating changes or sweating asymmetry
Motor/trophic	Evidence of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin)
- 4. No other diagnosis can better explain the symptoms and signs**

4. No other diagnosis can better explain the symptoms and signs

changes (hair, nail, skin)

decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic

CLINICAL FEATURES

Negative Symptoms

Positive Symptoms

Autonomic Symptoms

Motor/trophic symptoms



SYMPTOMS

Negative

Hypoesthesia

Sensory loss

Positive

Burning pain

Allodynia

Hyperalgesia



VASOMOTOR

- Temperature
- Colour



SUDOMOTOR CHANGES

Look for asymmetry of signs
and symptoms of:

Oedema

Sweating



MOTOR/TROPHIC SYMPTOMS

- Motor Changes
 - Weakness & Tremor
 - Reduced range of motion
 - Dystonia
- Trophic Changes
 - Hair & nail growth
 - Skin changes

KEY POINTS IN DIAGNOSIS

Use the Budapest criteria, but understand its limitations

Type I vs Type II CRPS is somewhat arbitrary.

Remember to exclude other conditions.

Generally only affects one limb

But it can spread

Don't need to wait 3 months - and you shouldn't



PainScience

PATHOPHYSIOLOGY



PATHOPHYSIOLOGY

Inflammation

Sympathetic dysfunction

Autoimmune

Central Sensitisation

Limb Ischaemia

Cortical Reorganisation

Nerve Damage

INFLAMMATION

Pro-inflammatory immune response

Proliferation of keratinocytes and release of:


IL-6, IL-1 β , TNF- α ;

Histamine (warm phase)

Activation of osteoblasts and osteoclasts

Antigen mediated T cell response

Increased IL-10, decreased IL-37



INFLAMMATION & PAIN FIBRES

C-fibre activation

Afferent pain signals

Efferent neuropeptides

CGRP, Substance P

Keratinocyte proliferation

A- α nerve fibre degeneration

A- δ nerve fibres preserved

AUTONOMIC NERVOUS SYSTEM

Acute Phase

Reduced sympathetic activity

Up regulation of α_1 adrenergic receptors

Increased pain with α_1 agonists


Chronic Phase

Increased sympathetic activity

Increased cytokines

endothelin-1

noradrenaline



sympathetic innervation

AUTOIMMUNE CHANGES

Elevated autoantibodies in serum - IgG, IgM

Pain levels are proportionate to elevations in IgG


Antibodies have α_1 , β_2 Adrenergic
& M_2 Muscarinic agonist activity

IgM autoantibodies produce pain via

Direct action on targets

Complement activation

Deposition of antibodies



GENETICS

Tends to run within families

HLA DRB1 unregulated, HLA-DQB1 downregulated

Other HLA associations: DQ1, DQ8, DR6, DR13, B62


Role of HLA is to present antigens.

Epigenetic modification of CpG sites

Mostly hypomethylation of sites related to immune function.

Genetic associations:

β 2 adrenoceptor polymorphisms, TNF α polymorphism





PainScience

CLINICAL COURSE



CLINICAL COURSE

Three broad phases

Warm (Acute inflammatory) phase

Cold (Chronic inflammatory) phase

Trophic phase - Probably an extension of the cold phase

Only 2% have relapsing/remitting phase

Phases aren't always present

CLINICAL COURSE

At 6 years after disease onset

30% of patients completely recovered

54% stable disease.

15% no improvement

Overall 30% of those who worked previously remain unable to work.

INVESTIGATIONS

Limited value in CRPS

X-ray

Bony excavations, resorption, demineralisation

MRI

Effusions, marrow oedema



PainScience

TREATMENT OPTIONS

MULTIDISCIPLINARY TEAM

Physiotherapy / Occupational Therapy

Mirror box therapy

Graded Motor Therapy

Desensitisation

Clinical Psychology

CBT & ACT



PHARMACOTHERAPY

NON STEROIDAL ANTI-INFLAMMATORY DRUGS

Traditional treatment, but actually little evidence

Non significant reduction of CRPS 500mg aspirin daily in one study.

STEROIDS

Prednisolone has some evidence.

Exact dose and duration not well established.

One study with benefit: 60mg daily for 28 days for acute phase

Superior to NSAID's

Not beneficial in chronic phase

ANTIOXIDANTS

Vitamin C - 500mg/day for 45-50 days

Some evidence for dose of 500-1000mg /day most effective

Less evidence for

Fish oil

NAC 600mg/day

Dimethylsulphoxide (DMSO) cream

BIPHOSPHONATES

Several studies show benefit

Modulate inflammatory mediator, migration of marrow cells.

Pamidronate 60mg IV equal effectiveness as prednisolone

ANTINEUROPATHIC AGENTS

Effectiveness is unclear, but some studies show benefit.

Gabapentin up to 1800mg/day

Similar results shown for amitriptyline in some studies

Standard neuropathic treatment options probably apply here

LIMITED EVIDENCE FOR SOME AGENTS

Ketamine:

Some evidence for intravenous and topical ketamine

No large RCT studies to date

Naltrexone - limited evidence for CRPS

Botox - significant reduction in pain in refractory CRPS

Plasma exchange therapy

CBD - reduction in pain scores in one study.


LACKING EVIDENCE

Capsacin

IT baclofen

IV Local anaesthetic

Pregabalin



NEUROMODULATION



TRANSCRANIAL MAGNETIC STIMULATION

Magnetic pulses to induce cortical stimulation

Evidence that it reduces pain

Effect persists beyond duration of treatment.

Limited evidence to date.



EPIDURAL BLOCKADE

Some evidence for sympathetic blockade at level of pain.

Most get pain reduction at time of procedure. Most get 1-4 weeks of benefit, a small number get persistent benefit

Stellate ganglion block may be of benefit for similar reasons



NEUROMODULATION

Spinal Cord Stimulation

Benefit seen for CRPS

Now getting >80% reduction in pain for most patients

Still some question about longer term efficacy.

OTHER INTERVENTIONS

Physiotherapy - Esp for upper limb

SCRAMBLER - May have some benefit

TENS - No evidence

OT - Some benefit

SURGERY

Sympathectomy

Some evidence for pain benefit

Amputation

No evidence.



SUMMARY

Definition

Diagnosis

Pathophysiology

Management